Abstract: The present disclosure provides compositions that inhibit the SH2-containing inositol 5?phosphatase (SHIP) as well as methods using such composition for use in treating or ameliorating the effects of a medical condition in a subject. For examples, compositions including the general formula as disclosed herein are suitable for use herein.
Type:
Grant
Filed:
October 17, 2019
Date of Patent:
April 9, 2024
Assignee:
THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK
Abstract: The present invention relates to new pharmaceutical agents, and to their use in the treatment of proliferative diseases, such as cancer (in particular, brain cancer).
Type:
Grant
Filed:
August 30, 2022
Date of Patent:
March 26, 2024
Assignee:
The University of Sydney
Inventors:
Michael Kassiou, William Jorgensen, Lenka Munoz
Abstract: Compounds, such as compounds having Formula (I): wherein each variable is as described herein, that modulate the conversion of AMP to adenosine by 5?-nucleotidase, ecto, and compositions containing the compounds and methods for synthesizing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by 5?-nucleotidase, ecto is also provided.
Type:
Grant
Filed:
August 26, 2019
Date of Patent:
March 19, 2024
Assignee:
Arcus Biosciences, Inc.
Inventors:
Joel Beatty, Laurent Pierre Paul Debien, Samuel Lawrie Drew, Jeremy Fournier, Rebecca Louise Grange, Steven Donald Jacob, Jenna Leigh Jeffrey, Kenneth V. Lawson, Manmohan Reddy Leleti, Erick Allen Lindsey, Debashis Mandal, Jay Patrick Powers, Anh Thu Tran, Rhiannon Thomas-Tran, Xuelei Yan
Abstract: The present disclosure provides compounds of Formulas (I), (II), and pharmaceutically acceptable salts thereof. The compounds described herein are useful in treating proliferative diseases, for example, cancer (e.g., lung cancer), and infectious diseases (e.g., bacterial infections).
Type:
Grant
Filed:
July 12, 2022
Date of Patent:
March 5, 2024
Assignees:
Academia Sinica, National Taiwan University
Abstract: The present invention relates to a novel fused ring compound having urea structure that exhibits excellent NAMPT activating effect, and a method using the same for treating/preventing metabolic disorder, cardiovascular and kidney disease, mitochondrial disease, neurodegenerative disease, ocular disease, and muscle wasting disorder. The present invention provides a compound represented by following formula (I) or a pharmacologically acceptable salt: Formula (I) wherein A, B, R, R2 and R3 represent the same meanings as in the claims.
Type:
Grant
Filed:
July 3, 2019
Date of Patent:
March 5, 2024
Assignee:
SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE
Inventors:
Tsuyoshi Nakamura, Mayuko Akiu, Takashi Tsuji, Jun Tanaka, Koji Terayama, Mika Yokoyama, Anthony B. Pinkerton, Edward Hampton Sessions
Abstract: The invention relates to compounds of formula (I) with low cytotoxicity for blocking the ubiquitination-proteasome system in diseases. Accordingly, these compounds can be used in treatment of disorders including, but not limited to, cancers.
Abstract: A method for producing 6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxylic acid is disclosed that includes steps of adding hydrazine sulfate with 2-ketoglutaric acid in a container as a solid, adding water to the solid creating a heterogenous mixture of the hydrazine sulfate, 2-ketoglutaric acid and water, blending the heterogenous mixture for at least one hour, and measuring the heterogenous mixture to confirm that it has converted into 6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxylic acid. Hydrazine sulfate can be added to the 2-ketoglutaric acid in the container at a ratio of greater than 1.1. The compound 6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxylic acid (PCA) has many uses. It has been used for medical applications and as a building block and for medical applications. The compound is also a product of the remediation of hydrazine using 2-ketogluraric acid.
Type:
Grant
Filed:
May 17, 2021
Date of Patent:
February 27, 2024
Inventors:
Robert Blaskovic, Rudolfo Martinez, Nathan P Martinez, Cliffford J Unkefer
Abstract: The invention relates to 5-({6-amino-2-[4-(5-chloro-2-cyanophenyl)-5-methoxy-2-oxopyridin-1(2H)-yl]-3-methylhexanoyl}amino)pyrazolo[1,5-a]pyridine-3-carboxamide to processes for its preparation, to its use for the treatment and/or prophylaxis of diseases and to its use for the preparation of medicaments for the treatment and/or prophylaxis of diseases, in particular cardiovascular disorders, preferably thrombotic or thromboembolic disorders, and edemas, and also ophthalmic disorders, and its use to inhibit disturbing plasma kallikrein activity for the conduct of extracorporeal procedures and analytical assays.
Type:
Grant
Filed:
April 3, 2019
Date of Patent:
January 30, 2024
Assignee:
BAYER PHARMA AKTIENGESELLSCHAFT
Inventors:
Mario Lobell, Hartmut Schirok, Adrian Tersteegen
Abstract: The pyrrolo[3,2-c][1,7]naphthyridine-2-carboxylic acid compounds, identified as CK2 inhibitors, are useful as anticancer and/or antitumor agents, and as agents for treating other kinase-associated conditions including inflammation, pain, and certain immunological disorders, and other types of diseases such as diabetes, viral infection, neurodegenerative diseases.
Abstract: Provided is a method for decomposing a flavonoid glycoside, wherein a flavonoid glycoside-containing raw material is hydrothermally treated to decompose a flavonoid glycoside into a flavonoid.
Abstract: The present disclosure provides methods of increasing skin pigmentation in a subject in need thereof using salt-inducible kinase (SIK) inhibitors, such as macrocyclic compounds of Formula (I), bicyclic urea compounds of Formula (II), (III), and (IV), and compounds of Formula (V), (VI), (VI-A), or (VII). Also provided are pharmaceutical compositions, methods, and uses that include or involve a compound described herein.
Type:
Grant
Filed:
November 22, 2021
Date of Patent:
January 23, 2024
Assignees:
The General Hospital Corporation, Dana-Farber Cancer Institute, Inc.
Inventors:
David E. Fisher, Nisma Mujahid, Ryo Murakami, Nathanael S. Gray, Yanke Liang, Hwan Geun Choi
Abstract: The present disclosure provides a semi-synthetic method of dihydroquercetin, belonging to the field of synthesis of organic drugs. The semi-synthetic method includes the following steps: adding quercetin dihydrate to solvent water adjusted to be alkaline with an alkalizing reagent, heating and stirring to dissolve the mixture, and then adding thiourea dioxide under the protection of an inert gas to perform a reduction reaction, to obtain an endpoint reduction reaction solution; diluting the endpoint reduction reaction solution with water and cooling the resultant, and then acidizing, aging, and filtering the resultant to obtain a filtrate and a filter cake; extracting, washing, drying, concentrating, and repeatedly crystallizing the filtrate to obtain dihydroquercetin; and recycling the filter cake after being washed.
Type:
Grant
Filed:
May 7, 2022
Date of Patent:
January 23, 2024
Assignee:
HEFEI LIFEON PHARMACEUTICAL CO., LTD.
Inventors:
Junqiu Ji, Xiaochang Li, Qiao Li, Jun Chen, Bing Li, Ruru Liu, Xiaohong Zhao
Abstract: Compounds, compositions, and methods of use of such compounds and compositions are provided for reducing human dependency to nicotine. In one example, a method of treating an individual with an addiction to nicotine comprises administering to the individual a compound that is a structural analog of trans-cinnamaldehyde. Based on the administration, a rate at which nicotine is metabolized may be reduced, which in turn may reduce a desire for the individual to consume nicotine-containing products.
Abstract: Provided are a compound of the formula: (5-(2-(4-((3,5-difluoro-4-(trifluoromethoxy)benzyl)amino)butoxy)ethoxy)benzo[c][2,6]naphthyridine-8-carboxylic acid) or a pharmaceutically acceptable salt thereof and a pharmaceutical composition comprising the above compound, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
Type:
Grant
Filed:
April 14, 2023
Date of Patent:
January 9, 2024
Assignee:
Cambridge Enterprise Limited
Inventors:
Marko Juhana Hyvonen, Paul Brear, David Robert Spring, Paul Glossop
Abstract: Novel organoselenium compounds formed with folates that can be used to maximize anticancer activity of the organoselenium. Novel organoselenium compounds that can be used as a chemopreventive against cancer. These compounds may be present in pharmaceutical compositions and may be used in various treatment methods.
Type:
Grant
Filed:
August 7, 2023
Date of Patent:
December 19, 2023
Assignee:
KING FAISAL UNIVERSITY
Inventors:
Amr Negm, Saad Shaaban, Yasair S. Al-Faiz
Abstract: Fused compounds of Formula (I) and Formula (II), pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to major depressive disorder, treatment resistant depression, anxious depression, bipolar disorder), cancers and eye conditions. Wherein R1, R2, R2a, R3, R3a, R4, and R4a are defined herein.
Type:
Grant
Filed:
December 23, 2020
Date of Patent:
November 21, 2023
Assignee:
Janssen Pharmaceutica NV
Inventors:
Michael K. Ameriks, Gang Chen, Chaofeng Huang, Brian Ngo Laforteza, Suchitra Ravula, Emma Helen Southgate, Wei Zhang
Abstract: Use of the molecule with the following formula (I) for its fungicidal and/or bactericidal activity on fungi, oomycetes and/or pathogenic bacteria of plants and crop seeds.
Abstract: The present disclosure relates to derivatives of strigolactone and formulations thereof. The present disclosure also relates to methods of treating a plant to improve, for example, the yield, growth, or vigor of a plant. The disclosed strigolactone derivatives and formulations may be combined with a plant growth regulator, a fertilizer, an insecticide, an herbicide, a fungicide, a urease inhibitor, a nitrification inhibitor, and/or an excipient.
Type:
Grant
Filed:
November 16, 2018
Date of Patent:
October 17, 2023
Assignee:
Plant Response, Inc.
Inventors:
Navid Adnani, Jonathan Evans, Hans Holtan
Abstract: Provided is a pest control composition containing a novel iminopyridine derivative and other pest control agents. Provided is a pest control composition containing an iminopyridine derivative represented by the following Formula (I) and at least one of other pest control agents: [in the formula (I), Ar represents a 5- to 6-membered heterocycle which may be substituted, A represents a heterocycle having a 5- to 10-membered unsaturated bond including one or more nitrogen atoms, and has an imino group substituted with an R group at a position adjacent to the nitrogen atom present on the cycle, Y represents hydrogen, halogen and the like, and R represents any one of groups represented by the following Formulae (a) to (e), (y) or (z)].